SK125897A3 - Medicament with angiotensin converting enzyme (ace) inhibitors suitable for transdermal application - Google Patents

Medicament with angiotensin converting enzyme (ace) inhibitors suitable for transdermal application Download PDF

Info

Publication number: SK125897A3
Authority: SK; Slovakia
Prior art keywords: transdermal system; layer; adhesive; cover layer; self
Prior art date: 1995-03-31

Application number

SK1258-97A

Other languages

English (en)

Slovak (sk)

Inventor

Wilfried Fischer

Karin Klokkers

Anna Sendl-Lang

Original Assignee

Hexal Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-31

Filing date

1996-03-29

Publication date

1998-02-04

1996-03-29 Application filed by Hexal Ag filed Critical Hexal Ag

1998-02-04 Publication of SK125897A3 publication Critical patent/SK125897A3/sk

Links

239000003814 drug Substances 0.000 title description 3
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 title 1
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 title 1
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
239000005541 ACE inhibitor Substances 0.000 claims abstract description 25
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 25
229940100640 transdermal system Drugs 0.000 claims abstract description 23
239000010410 layer Substances 0.000 claims description 30
150000001875 compounds Chemical class 0.000 claims description 19
239000000853 adhesive Substances 0.000 claims description 17
239000011159 matrix material Substances 0.000 claims description 16
VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims description 12
229960002051 trandolapril Drugs 0.000 claims description 12
229920002367 Polyisobutene Polymers 0.000 claims description 11
239000012790 adhesive layer Substances 0.000 claims description 10
239000012528 membrane Substances 0.000 claims description 9
230000001070 adhesive effect Effects 0.000 claims description 8
-1 polypropylene Polymers 0.000 claims description 7
239000006260 foam Substances 0.000 claims description 6
239000011796 hollow space material Substances 0.000 claims description 6
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 5
229920005549 butyl rubber Polymers 0.000 claims description 5
229960003401 ramipril Drugs 0.000 claims description 5
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 5
239000004743 Polypropylene Substances 0.000 claims description 4
229920001155 polypropylene Polymers 0.000 claims description 4
229920001296 polysiloxane Polymers 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
229920000642 polymer Polymers 0.000 claims description 3
239000011148 porous material Substances 0.000 claims description 3
229940002612 prodrug Drugs 0.000 claims description 3
239000000651 prodrug Substances 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
229920002689 polyvinyl acetate Polymers 0.000 claims description 2
239000011118 polyvinyl acetate Substances 0.000 claims description 2
239000004698 Polyethylene Substances 0.000 claims 2
239000011248 coating agent Substances 0.000 claims 2
238000000576 coating method Methods 0.000 claims 2
229920000728 polyester Polymers 0.000 claims 2
229920000573 polyethylene Polymers 0.000 claims 2
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
229920001971 elastomer Polymers 0.000 claims 1
229920002635 polyurethane Polymers 0.000 claims 1
239000004814 polyurethane Substances 0.000 claims 1
239000008280 blood Substances 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
239000002775 capsule Substances 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000010408 film Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000036765 blood level Effects 0.000 description 3
229960000830 captopril Drugs 0.000 description 3
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
108010061435 Enalapril Proteins 0.000 description 2
229960004530 benazepril Drugs 0.000 description 2
229940079593 drug Drugs 0.000 description 2
229960000873 enalapril Drugs 0.000 description 2
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920006267 polyester film Polymers 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
108010066671 Enalaprilat Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000013039 cover film Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229960002680 enalaprilat Drugs 0.000 description 1
LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
229960002490 fosinopril Drugs 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000010224 hepatic metabolism Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000012153 long-term therapy Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
235000020938 metabolic status Nutrition 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000013464 silicone adhesive Substances 0.000 description 1
229920002379 silicone rubber Polymers 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Vascular Medicine (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SK1258-97A 1995-03-31 1996-03-29 Medicament with angiotensin converting enzyme (ace) inhibitors suitable for transdermal application SK125897A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19512181A DE19512181C2 (de)	1995-03-31	1995-03-31	Transdermales System mit Ramipril und/oder Trandolapril als ACE-Hemmer
PCT/EP1996/001402 WO1996029999A1 (fr)	1995-03-31	1996-03-29	Medicament a administration transdermique, comportant des inhibiteurs de l'enzyme de conversion de l'angiotensine

Publications (1)

Publication Number	Publication Date
SK125897A3 true SK125897A3 (en)	1998-02-04

Family

ID=7758491

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1258-97A SK125897A3 (en)	1995-03-31	1996-03-29	Medicament with angiotensin converting enzyme (ace) inhibitors suitable for transdermal application

Country Status (19)

Country	Link
US (1)	US6303141B1 (fr)
EP (1)	EP0817622B1 (fr)
JP (1)	JP3924008B2 (fr)
AT (1)	ATE209482T1 (fr)
AU (1)	AU700418B2 (fr)
BR (1)	BR9607872A (fr)
CA (1)	CA2216278A1 (fr)
CZ (1)	CZ287373B6 (fr)
DE (2)	DE19512181C2 (fr)
DK (1)	DK0817622T3 (fr)
ES (1)	ES2167558T3 (fr)
HU (1)	HUP9801989A3 (fr)
NO (1)	NO974508L (fr)
NZ (1)	NZ306429A (fr)
PL (1)	PL322576A1 (fr)
PT (1)	PT817622E (fr)
SK (1)	SK125897A3 (fr)
WO (1)	WO1996029999A1 (fr)
ZA (1)	ZA962592B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020048596A1 (en) *	1994-12-30	2002-04-25	Gregor Cevc	Preparation for the transport of an active substance across barriers
DE19820151A1 (de) *	1998-05-06	1999-11-11	Hexal Ag	Transdermales therapeutisches System zur Anwendung von Candesartan
DE69825495T2 (de)	1998-12-23	2005-07-28	Idea Ag	Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
SI1031347T1 (en)	1999-01-27	2002-10-31	Idea Ag	Transnasal transport/immunisation with highly adaptable carriers
PT1031346E (pt)	1999-01-27	2002-09-30	Idea Ag	Vacinacao nao invasiva atraves da pele
WO2001001962A1 (fr)	1999-07-05	2001-01-11	Idea Ag.	Procede d'amelioration du transport a travers des barrieres semi-permeables compatibles
DE10033855A1 (de) *	2000-07-12	2002-01-31	Hexal Ag	Matrixkontrolliertes transdermales System mit Sulfonsäuresalz eines ACE-Hemmers
DE10033853A1 (de) *	2000-07-12	2002-01-31	Hexal Ag	Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
KR100988542B1 (ko) *	2001-06-18	2010-10-20	노벤 파머수티컬즈, 인코퍼레이티드	경피 시스템에서의 강화된 약물 전달
US6805878B2 (en) *	2001-09-13	2004-10-19	Noven Pharmaceuticals, Inc.	Transdermal administration of ACE inhibitors
US20040105881A1 (en) *	2002-10-11	2004-06-03	Gregor Cevc	Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
CA2584475A1 (fr) *	2004-11-12	2006-05-18	Idea Ag	Agregats a grande surface pour le traitement de troubles cutanes
EP1704876A1 (fr) *	2005-03-24	2006-09-27	NOLabs AB	Traitement cosmétique, dispositif pour application du traitment et méthode de production
EP1871433B1 (fr)	2005-03-24	2009-04-22	NOLabs AB	Traitement cosmétique, dispositif pour application du traitment et méthode de production
JP5058531B2 (ja)	2005-09-09	2012-10-24	日東電工株式会社	ビソプロロール含有貼付製剤
DE102005058166A1 (de)	2005-12-05	2007-06-06	Hexal Ag	Matrixkontrolliertes transdermales System mit Amin-Salzen der ACE-Hemmer-Dicarbonsäuren
JP4945228B2 (ja) *	2005-12-13	2012-06-06	日東電工株式会社	ビソプロロール含有貼付製剤
JP5015562B2 (ja) *	2005-12-13	2012-08-29	日東電工株式会社	貼付製剤
US7943655B2 (en) *	2006-04-05	2011-05-17	Universitat Zurich	Polymorphic and pseudopolymorphic forms of trandolaprilat, pharmaceutical compositions and methods for production and use
CN103784425B (zh)	2007-03-08	2016-08-17	日东电工株式会社	比索洛尔的经皮给药装置
ES2804263T3 (es)	2011-07-05	2021-02-05	Novan Inc	Composiciones tópicas
US9855211B2 (en)	2013-02-28	2018-01-02	Novan, Inc.	Topical compositions and methods of using the same
US11813284B2 (en)	2013-08-08	2023-11-14	Novan, Inc.	Topical compositions and methods of using the same
EP3177262A4 (fr)	2014-08-08	2018-04-18	Novan Inc.	Émulsions topiques
US10912743B2 (en)	2016-03-02	2021-02-09	Novan, Inc.	Compositions for treating inflammation and methods of treating the same
US11166980B2 (en)	2016-04-13	2021-11-09	Novan, Inc.	Compositions, systems, kits, and methods for treating an infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5256687A (en) *	1985-09-09	1993-10-26	Hoechst Aktiengesellschaft	Pharmaceutical composition for the treatment of high blood pressure
US5656286A (en) *	1988-03-04	1997-08-12	Noven Pharmaceuticals, Inc.	Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4898732A (en) *	1988-05-04	1990-02-06	The Clinipad Corporation	Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
US5269875A (en)	1989-10-05	1993-12-14	Shin-Etsu Handotai Company, Limited	Method of adjusting concentration of oxygen in silicon single crystal and apparatus for use in the method
JPH0774116B2 (ja) *	1989-10-05	1995-08-09	信越半導体株式会社	Ｓｉ単結晶中の酸素濃度調整方法およびその装置
US5073539A (en) *	1990-01-22	1991-12-17	Ciba-Geigy Corporation	Transdermal administration of zwitterionic drugs
JP2849937B2 (ja)	1990-04-18	1999-01-27	日東電工株式会社	医療用貼付剤
FR2664815B1 (fr)	1990-07-23	1994-11-04	Adir	Systeme matriciel autoadhesif pour la liberation prolongee du piribedil par voie transcutanee.
US5464387A (en) *	1991-07-24	1995-11-07	Alza Corporation	Transdermal delivery device
WO1993023019A1 (fr) *	1992-05-11	1993-11-25	Sri International	Dispositifs d'apport medicamenteux transcutane, compositions qui y sont associees et procedes d'utilisation

1995
- 1995-03-31 DE DE19512181A patent/DE19512181C2/de not_active Expired - Fee Related
1996
- 1996-03-29 ES ES96911973T patent/ES2167558T3/es not_active Expired - Lifetime
- 1996-03-29 CZ CZ19973028A patent/CZ287373B6/cs unknown
- 1996-03-29 NZ NZ306429A patent/NZ306429A/en unknown
- 1996-03-29 CA CA002216278A patent/CA2216278A1/fr not_active Abandoned
- 1996-03-29 DK DK96911973T patent/DK0817622T3/da active
- 1996-03-29 PL PL96322576A patent/PL322576A1/xx unknown
- 1996-03-29 DE DE59608323T patent/DE59608323D1/de not_active Expired - Lifetime
- 1996-03-29 BR BR9607872-3A patent/BR9607872A/pt not_active Application Discontinuation
- 1996-03-29 AT AT96911973T patent/ATE209482T1/de active
- 1996-03-29 WO PCT/EP1996/001402 patent/WO1996029999A1/fr not_active Ceased
- 1996-03-29 JP JP52894896A patent/JP3924008B2/ja not_active Expired - Fee Related
- 1996-03-29 SK SK1258-97A patent/SK125897A3/sk unknown
- 1996-03-29 HU HU9801989A patent/HUP9801989A3/hu unknown
- 1996-03-29 EP EP96911973A patent/EP0817622B1/fr not_active Expired - Lifetime
- 1996-03-29 AU AU54982/96A patent/AU700418B2/en not_active Ceased
- 1996-03-29 PT PT96911973T patent/PT817622E/pt unknown
- 1996-04-01 ZA ZA9602592A patent/ZA962592B/xx unknown
1997
- 1997-09-29 NO NO974508A patent/NO974508L/no not_active Application Discontinuation
1999
- 1999-09-29 US US09/407,348 patent/US6303141B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU700418B2 (en)	1999-01-07
CZ302897A3 (cs)	1998-02-18
MX9707507A (es)	1997-11-29
WO1996029999A1 (fr)	1996-10-03
BR9607872A (pt)	1999-11-30
HUP9801989A3 (en)	2000-06-28
DE59608323D1 (de)	2002-01-10
CA2216278A1 (fr)	1996-10-03
US6303141B1 (en)	2001-10-16
DE19512181A1 (de)	1996-10-02
NZ306429A (en)	2000-07-28
ES2167558T3 (es)	2002-05-16
HUP9801989A2 (hu)	1999-02-01
ZA962592B (en)	1997-10-01
EP0817622A1 (fr)	1998-01-14
ATE209482T1 (de)	2001-12-15
NO974508L (no)	1997-10-27
DE19512181C2 (de)	2003-11-06
EP0817622B1 (fr)	2001-11-28
NO974508D0 (no)	1997-09-29
PT817622E (pt)	2002-05-31
PL322576A1 (en)	1998-02-02
JP3924008B2 (ja)	2007-06-06
DK0817622T3 (da)	2002-03-25
CZ287373B6 (en)	2000-11-15
JPH11502827A (ja)	1999-03-09
AU5498296A (en)	1996-10-16

Publication	Publication Date	Title
SK125897A3 (en)	1998-02-04	Medicament with angiotensin converting enzyme (ace) inhibitors suitable for transdermal application
US9248104B2 (en)	2016-02-02	Transdermal methods and systems for treating Alzheimer's disease
US5091186A (en)	1992-02-25	Biphasic transdermal drug delivery device
US20190192506A1 (en)	2019-06-27	Transdermal therapeutic system for administering the active substance buprenorphine
EP1503743B1 (fr)	2007-01-24	Systeme d'administration transdermique comportant deux couches adhesives superposees ayant des affinites differentes par rapport a la substance active contenue
US20120323190A1 (en)	2012-12-20	Percutaneous Absorption Preparation Comprising Anti-Dementia Drug
CA2651596A1 (fr)	2007-11-15	Preparations de medicaments contre la demence absorbees par voie percutanee
KR20010036685A (ko)	2001-05-07	펜타닐을 함유하는 매트릭스형 경피투여제
AU2021260149A1 (en)	2022-09-29	Oral delivery system comprising hydroxychloroquine and/or chloroquine
US5176917A (en)	1993-01-05	Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances
AU2021256454A1 (en)	2022-09-29	Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
CN109689527B (zh)	2021-02-19	包含哌甲酯或其盐的透皮递送系统及其方法
MXPA97007507A (en)	1998-07-03	Transdermically administrative medicine with inhibitors
CN1179712A (zh)	1998-04-22	含有ace抑制剂的透皮给药系统
HK40084062A (en)	2023-07-07	Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
HK1018199A (en)	1999-12-17	Transdermally administrable medicament with ace inhibitors
HK40002940A (en)	2020-04-03	Transdermal delivery system containing methylphenidate or its salts and methods thereof
HK1179184A (en)	2013-09-27	Transdermally absorbed preparation of anti-dementia drug
HK1179184B (en)	2014-11-21	Transdermally absorbed preparation of anti-dementia drug